Allergan Inc. Blog | Talkmarkets | Page 1

Allergan Inc.

Get instant email alerts
Exchange: Sector: Industry:
NYSE HEALTHCARE Drug Manufacturers - Other

People who follow this stock (57)

Latest Posts

About This Stock More About This Stock
Allergan (AGN) Beats Q3 Earnings, Sales In Line, Stock Up
Article By: Zacks Investment Research
Wednesday, November 1, 2017 11:07 AM EST
Allergan’s third-quarter earnings of $4.15 per share were above our consensus estimate of $4.06 per share.
In this article: AGN
Is Allergan Stock Finally Going To Reward Shareholders?
Article By: Modest Money
Thursday, October 19, 2017 12:31 PM EST
Allergan Stock has been a painful ride for investors. Starting last year when the proposed merger with Pfizer fell through, Allergan stock has fallen.
In this article: AGN
Allergan Says Mohawks Bought Restasis Patents With Immunity Promise
Article By: Shock Exchange
Friday, October 13, 2017 10:36 AM EST
AGN the Mohawks brought Restasis patents with a promise of immunity. I estimate the patents are worth $14B. The patent judge want to determine if the deal was a sham.
In this article: AGN Also: MYL, TEVA
Senator Thwarts Allergan's Patent Transfer, Inflaming The Mohawks
Article By: Shock Exchange
Friday, October 6, 2017 5:51 PM EST
Senator Claire McCaskill drafted a bill to thwart the transfer of AGN's Restasis patents to the Mohawk Tribe. Next steps could be to push for Medicare Part D access for SHPG's Xiidra and prioritize clinical stage drugs from RGRX or ALDX.
In this article: AGN Also: SHPG, RGRX, ALDX, TEVA, IMMY
Pharma Stock Roundup: Mylan Up, Teva Down On Copaxone News, Lawmakers Question Allergan Deal
Article By: Arpita Dutt
Friday, October 6, 2017 10:31 AM EST
While Mylan and Teva were in the news related to the FDA approval of Mylan’s generic versions of Teva’s top-selling branded drug, Copaxone, Allergan is under fire for its agreement with the Saint Regis Mohawk Tribe for Restasis.
In this article: AGN, TEVA, MYL Also: NVO, SNY, LLY, GSK


Latest Tweets for $AGN

No tweets yet!


Valeant Edges Up 15% After Announcing That It Will Acquire Salix
Terry Caruso 2/24/2015 8:20:44 PM

You said the company tried to acquire Allergan but the deal fell through because Valeant didn't like it's large R&D program. If true, why did it try to acquire $AGN in the first place?

1 to 1 of 1 comments